Related Experiment Video
Updated: Jul 8, 2026
09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Role of uric acid in multiple sclerosis
1Thomas Jefferson University, 1020 Locust St, JAH Room M85, Philadelphia, PA 19107, USA.
Current Topics in Microbiology and Immunology
|January 29, 2008
Summary
Free radicals contribute to aging and disease. Research explores the link between lower uric acid (UA) levels and multiple sclerosis (MS) pathology, investigating potential treatments.
Area of Science:
- Neurology
- Oxidative Stress Research
- Biochemistry
Background:
- Free radicals are implicated in aging, cancer, and heart disease.
- Oxidative damage is evident in multiple sclerosis (MS) central nervous system (CNS) pathology.
- Antioxidant therapies for MS have shown limited success.
Purpose of the Study:
- To review evidence linking uric acid (UA) levels to MS.
- To discuss the role of UA as a scavenger of reactive nitrogen species.
- To explore current strategies for manipulating serum UA in MS patients.
Main Methods:
- Literature review of studies on UA levels in MS patients.
- Analysis of research on oxidative stress in CNS diseases.
- Discussion of therapeutic approaches targeting UA.
Main Results:
- Conflicting findings exist regarding UA levels in MS patients.
- Some studies report lower UA levels in MS, while others show no correlation.
- UA's role as a reactive nitrogen species scavenger is established.
Conclusions:
- The relationship between UA levels and MS requires further investigation.
- Manipulating serum UA is a potential therapeutic avenue for MS.
- Understanding UA's role may offer new insights into MS pathogenesis.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...